Wage Hope to end pancreatic cancer
Our team has stepped up to Wage Hope at PurpleStride, to help end pancreatic cancer. Will you help us rewrite the future of this disease by making a donation today?
Every dollar that you donate ensures that the Pancreatic Cancer Action Network can continue working to create better outcomes for pancreatic cancer patients and their families. By donating to our team, you are supporting vital efforts to double pancreatic cancer survival by 2020.
Please join us in the fight today.
• While surgery (often the Whipple procedure) offers the best chance for survival, fewer than 20 percent of pancreatic cancer cases are diagnosed early enough for surgical intervention. Even with surgery, the disease recurs in approximately 80 percent of these patients, who die within five years of recurrence.
• For non-surgical candidates, chemotherapy — possibly with radiation — is typically offered, but is not considered curative.
• Since 1974, only four drugs have been approved by the U.S. Food & Drug Administration (FDA) to treat pancreatic cancer: gemcitabine (Gemzar®) in 1996, erlotinib (Tarceva®) in 2005, albumin-bound paclitaxel (Abraxane®) in 2013 and irinotecan liposome injection (Onivyde™) in 2015. In 2011, a combination chemotherapy regimen called FOLFIRINOX was found to improve survival of metastatic pancreatic cancer patients. While these new treatments and combinations have recently been shown to extend the lives of pancreatic cancer patients, the improvement is small, and the vast majority of patients still rapidly succumb to their disease.